Eight months af­ter fil­ing for IPO, the mak­er of Chi­na's Ebo­la vac­cine joins HKEX with $161M raise

The Hong Kong stock ex­change is wel­com­ing its first pre-rev­enue vac­cine mak­er on board.

Tian­jin-based CanSi­no scored $160.5 mil­lion in an IPO by sell­ing 57.2 mil­lion shares at $2.8, or HK$22, the top of the range. Around 40% of the cap­i­tal came from lo­cal in­vestors and the rest went to in­ter­na­tion­al com­mu­ni­ty, both of which over­sub­scribed. The pub­lic de­but donned a val­u­a­tion of $611.6 mil­lion, ac­cord­ing to Bio­Cen­tu­ry.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER